TTM
$2.04
YoY change
-0.8%
5Y CAGR
-2.7%
Peak year (2022)
$6.63
Latest annual
$2.37
EPS (Diluted) history chart for AbbVie (ABBV) from 2009 to 2025
Latest: $2.37
EPS (Diluted) growth chart for AbbVie (ABBV) from 2009 to 2025
Latest: -0.8%
EPS (Diluted) history table for AbbVie (ABBV) from 2009 to 2025
| 2025 | $2.37 | -0.8% | −$0.02 | ||
| 2024 | $2.39 | -12.1% | −$0.33 | ||
| 2023 | $2.72 | -59.0% | −$3.91 | ||
| 2022 | $6.63 | +2.8% | +$0.18 | ||
| 2021 | $6.45 | +137.1% | +$3.73 | ||
| 2020 | $2.72 | -48.5% | −$2.56 | ||
| 2019 | $5.28 | +43.5% | +$1.60 | ||
| 2018 | $3.68 | +11.5% | +$0.38 | ||
| 2017 | $3.30 | -9.1% | −$0.33 | ||
| 2016 | $3.63 | +16.0% | +$0.50 | ||
| 2015 | $3.13 | +184.5% | +$2.03 | ||
| 2014 | $1.10 | -57.0% | −$1.46 | ||
| 2013 | $2.56 | -23.6% | −$0.79 | ||
| 2012 | $3.35 | +58.8% | +$1.24 | ||
| 2011 | $2.11 | -17.9% | −$0.46 | ||
| 2010 | $2.57 | -9.8% | −$0.28 | ||
| 2009 | $2.85 | — | — |
- 2025$2.37-0.8%
- 2024$2.39-12.1%
- 2023$2.72-59.0%
- 2022$6.63+2.8%
- 2021$6.45+137.1%
- 2020$2.72-48.5%
- 2019$5.28+43.5%
- 2018$3.68+11.5%
- 2017$3.30-9.1%
- 2016$3.63+16.0%
- 2015$3.13+184.5%
- 2014$1.10-57.0%
- 2013$2.56-23.6%
- 2012$3.35+58.8%
- 2011$2.11-17.9%
- 2010$2.57-9.8%
- 2009$2.85—
EPS (Diluted) values are taken from AbbVie's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EPS (Diluted) at AbbVie (ABBV)
According to AbbVie's latest reported financial statements, the company's current diluted EPS (TTM) is $2.04. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, AbbVie (ABBV) diluted EPS totalled $2.37 – edged down 0.8% year-over-year.
AbbVie diluted EPS compound annual growth for the 2020–2025 (5 years) window is -2.7%, with a net decline across the window.
Between 2022 and 2025, AbbVie diluted EPS plunged 64.3%, falling from $6.63 to $2.37.
$6.63 stands as the all-time-high annual diluted EPS, posted in 2022, against a low of $1.10 during 2014.
AbbVie EPS (Diluted) by Year
AbbVie EPS (Diluted) 2025: $2.37
AbbVie diluted EPS in 2025 was $2.37, edged down 0.8% below 2024.
AbbVie EPS (Diluted) 2024: $2.39
2024's diluted EPS for AbbVie came in at $2.39, declined 12.1% below 2023.
AbbVie EPS (Diluted) 2023: $2.72
AbbVie posted diluted EPS of $2.72 in 2023, plunged 59.0% below 2022.
AbbVie EPS (Diluted) 2022: $6.63
In 2022, AbbVie reported diluted EPS of $6.63, edged up 2.8% from 2021. This figure represents the highest annual value in the available history.
AbbVie EPS (Diluted) 2021: $6.45
AbbVie diluted EPS in 2021 was $6.45.
See more financial history for AbbVie (ABBV). Or calculate EPS yourself.
Sector peers by EPS (Diluted)
Healthcare peers of AbbVie (ABBV), ranked by their latest diluted EPS
| $22.95 | |
| $17.74 | |
| $14.23 | |
| $13.23 | |
| $11.03 | |
| $7.28 | |
| $6.54 | |
| $3.59 |
- $22.95
- $14.23
- $13.23
- $11.03
- $7.28
- $6.54
- $3.59
Frequently asked questions
AbbVie (ABBV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation